Biocon
BSE 532523
4 stories, newest first.
- Global patent settlement with Genentech secures earliest licensed launch dates for Pebrilzo® (bPertuzumab)
- GST Order Confirms Rs. 1,85,28,762 Demand, Rs. 1,17,59,033 Interest, Rs. 18,52,476 Penalty
- 94,60,232 employee stock options granted under Biocon Unity Long Term Incentive Plan 2026
- Biocon Malaysia Receives MHRA Approval for Insulin Fill-Finish Unit
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.